Kymera Therapeutics
KYMR
121 hedge funds and large institutions have $797M invested in Kymera Therapeutics in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 49 increasing their positions, 36 reducing their positions, and 19 closing their positions.
1,015% more call options, than puts
Call options by funds: $680K | Put options by funds: $61K
36% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 36
2.12% less ownership
Funds ownership: 105.62% → 103.5% (-2.1%)
5% less funds holding
Funds holding: 128 → 121 (-7)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
41% less capital invested
Capital invested by funds: $1.34B → $797M (-$547M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$7.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.66M |
| 3 |
BlackRock
New York
|
+$2.65M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$2.63M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.8M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$12.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$4.2M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.73M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$3.5M |
KYMR Hedge Fund Activity: Q3 2023 in Review
121 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q3 2023, worth a combined $797M — down 41% from $1.34B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KYMR and 12 opened new positions — a net loss of 7 holders — while 36 trimmed existing stakes and 49 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $7.54M. The largest seller was State Street, cutting an estimated $12.8M.
- 121 institutional investors held Kymera Therapeutics (KYMR) as of Q3 2023, down from 128 in Q2 2023.
- Funds reported $797M of Kymera Therapeutics stock for Q3 2023, down 41% quarter-over-quarter.
- 12 funds opened new Kymera Therapeutics positions in Q3 2023 and 19 closed out, a net change of -7 holders.
- The largest Kymera Therapeutics buyer in Q3 2023 was Baker Bros. Advisors, an estimated $7.54M added.
- The largest Kymera Therapeutics seller in Q3 2023 was State Street, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2023.